Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
Earnings Data
Report Date
Mar 04, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
1.54Last Year’s EPS
1.27Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant growth in core revenue and EPS, an increase in full-year guidance, and successful financial transactions. However, there are some concerns related to increased operating expenses and limited information on the ZELSUVMI launch.Company Guidance
Strong Financial Performance
Core revenue grew 68% year-over-year to $86.9 million, and adjusted EPS increased 68% to $3.09. Royalty revenue rose 47% year-over-year to $46.6 million.
Increased Full-Year Guidance
Ligand raised its full-year 2025 guidance with core revenue now expected to be between $225 million and $235 million, and adjusted EPS between $7.40 and $7.65.
Successful Convertible Debt Financing
Ligand successfully completed a $460 million convertible note financing with a favorable 75 basis point coupon rate and a 32.5% conversion premium.
Ohtuvayre and FILSPARI Performance
Ohtuvayre sales grew 32% sequentially, and FILSPARI sales increased 26% over the prior quarter, becoming Ligand's largest royalty-generating asset on an annualized basis.
Positive Developments in Key Assets
Merck's CAPVAXIVE sales increased significantly, and Palvella's QTORIN rapamycin program shows promising potential with upcoming Phase III results.
LGND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LGND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $190.38 | $208.22 | +9.37% |
Aug 07, 2025 | $142.40 | $146.32 | +2.75% |
May 08, 2025 | $105.62 | $102.51 | -2.94% |
Feb 27, 2025 | $115.01 | $115.67 | +0.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ligand Pharma (LGND) report earnings?
Ligand Pharma (LGND) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).
What is Ligand Pharma (LGND) earnings time?
Ligand Pharma (LGND) earnings time is at Mar 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGND EPS forecast?
LGND EPS forecast for the fiscal quarter 2025 (Q4) is 1.54.